Unicycive Accounts Payable from 2010 to 2024

UNCY Stock  USD 0.55  0.02  3.77%   
Unicycive Therapeutics Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable will likely drop to about 540.1 K in 2024. Accounts Payable is the amount Unicycive Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Unicycive Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
821 K
Current Value
540.1 K
Quarterly Volatility
306 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Unicycive Therapeutics over the last few years. An accounting item on the balance sheet that represents Unicycive Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Unicycive Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Unicycive Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Unicycive Accounts Payable Regression Statistics

Arithmetic Mean264,407
Geometric Mean140,245
Coefficient Of Variation115.74
Mean Deviation256,009
Median60,000
Standard Deviation306,024
Sample Variance93.7B
Range786K
R-Value0.80
Mean Square Error36B
R-Squared0.64
Significance0.0003
Slope54,874
Total Sum of Squares1.3T

Unicycive Accounts Payable History

2024540.1 K
2023821 K
2022846 K
2021713 K
2020184 K
2019322 K

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable821 K540.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.